<DOC>
	<DOCNO>NCT00902070</DOCNO>
	<brief_summary>The main purpose investigation collect safety efficacy information Eslax Intravenous 25mg/2.5mL 50mg/5.0mL ( hereinafter refer `` Eslax '' ) daily clinical setting .</brief_summary>
	<brief_title>Protocol Eslax Intravenous Drug Use Investigation ( Study P06082 )</brief_title>
	<detailed_description>Post-marketing survey consider applicable clinical trial thus result survey post conclusion . The result submit public health official require applicable national international law .</detailed_description>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>Patients Eslax administer relax muscle time anesthesia tracheal intubation . Patients history hypersensitivity Eslax bromide . Patients myasthenia gravis myasthenic syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>